EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 39 / No 12 (Décembre 2023) Med Sci (Paris), 39 12 (2023) 917-920 References
Free Access
Issue
Med Sci (Paris)
Volume 39, Number 12, Décembre 2023
Page(s) 917 - 920
Section Nouvelles
DOI https://doi.org/10.1051/medsci/2023171
Published online 18 December 2023
  1. Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med 2016 ; 374 : 2209–2221. [Google Scholar]
  2. Döhner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 2022; 140 : 1345–77. [CrossRef] [PubMed] [Google Scholar]
  3. DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med 2020; 383 : 617–29. [CrossRef] [PubMed] [Google Scholar]
  4. Patnaik MM. The importance of FLT3 mutational analysis in acute myeloid leukemia. Leuk. Lymphoma 2018 ; 59 : 2273–2286. [CrossRef] [PubMed] [Google Scholar]
  5. Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med 2017 ; 377 : 454–464. [CrossRef] [PubMed] [Google Scholar]
  6. Erba HP, Montesinos P, Kim H-J, et al. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2023; 401 : 1571–83. [CrossRef] [PubMed] [Google Scholar]
  7. Perl AE, Martinelli G, Cortes JE, et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N Engl J Med 2019 ; 381 : 1728–1740. [CrossRef] [PubMed] [Google Scholar]
  8. McMahon CM, Ferng T, Canaani J, et al. Clonal selection with RAS pathway activation mediates secondary clinical resistance to selective FLT3 inhibition in acute myeloid leukemia. Cancer Discov 2019 ; 9 : 1050–1063. [CrossRef] [PubMed] [Google Scholar]
  9. Alotaibi AS, Yilmaz M, Kanagal-Shamanna R, et al. Patterns of resistance differ in patients with acute myeloid leukemia treated with type I versus type II FLT3 inhibitors. Blood Cancer Discov 2021; 2 : 125–34. [CrossRef] [PubMed] [Google Scholar]
  10. Martínez-Reyes I, Chandel NS. Cancer metabolism: looking forward. Nat Rev Cancer 2021; 21 : 669–80. [CrossRef] [PubMed] [Google Scholar]
  11. Hanahan D. Hallmarks of cancer: New dimensions. Cancer Discov 2022; 12 : 31–46. [CrossRef] [PubMed] [Google Scholar]
  12. Ju H-Q, Zhan G, Huang A, et al. ITD mutation in FLT3 tyrosine kinase promotes Warburg effect and renders therapeutic sensitivity to glycolytic inhibition. Leukemia 2017 ; 31 : 2143–2150. [CrossRef] [PubMed] [Google Scholar]
  13. Gallipoli P, Giotopoulos G, Tzelepis K, et al. Glutaminolysis is a metabolic dependency in FLT3ITD acute myeloid leukemia unmasked by FLT3 tyrosine kinase inhibition. Blood 2018 ; 131 : 1639–1653. [CrossRef] [PubMed] [Google Scholar]
  14. Bjelosevic S, Gruber E, Newbold A, et al. Serine biosynthesis is a metabolic vulnerability in FLT3-ITD-driven acute myeloid leukemia. Cancer Discov 2021; 11 : 1582–99. [CrossRef] [PubMed] [Google Scholar]
  15. Birsen R, Grignano E, Chapuis N, et al. Ferroptose et cancer : implications physiopathologiques et thérapeutiques. Med Sci (Paris) 2021; 37 : 726–34. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  16. Sen U, Coleman C, Sen T. Stearoyl coenzyme A desaturase-1: multitasker in cancer, metabolism, and ferroptosis. Trends Cancer 2023; 9 : 480–9. [CrossRef] [PubMed] [Google Scholar]
  17. Sabatier M, Birsen R, Lauture L, et al. C/EBPα confers dependence to fatty acid anabolic pathways and vulnerability to lipid oxidative stress-induced ferroptosis in FLT3-mutant leukemia. Cancer Discov 2023; 13 : 1720–47. [CrossRef] [PubMed] [Google Scholar]
  18. Zou Y, Palte MJ, Deik AA, et al. A GPX4-dependent cancer cell state underlies the clear-cell morphology and confers sensitivity to ferroptosis. Nat Commun 2019 ; 10 : 1617. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.